样式: 排序: IF: - GO 导出 标记为已读
-
Machine Learning Identifies Smartwatch-Based Physiological Biomarker for Predicting Disruptive Behavior in Children: A Feasibility Study. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-11-01 Magdalena Romanowicz,Kyle S Croarkin,Rana Elmaghraby,Michelle Skime,Paul E Croarkin,Jennifer L Vande Voort,Julia Shekunov,Arjun P Athreya
Objective: Parents frequently purchase and inquire about smartwatch devices to monitor child behaviors and functioning. This pilot study examined the feasibility and accuracy of using smartwatch monitoring for the prediction of disruptive behaviors. Methods: The study enrolled children (N = 10) aged 7-10 years hospitalized for the treatment of disruptive behaviors. The study team completed continuous
-
Growth Trajectories in Stimulant Treated Children and Adolescents: A Qualitative Review of the Literature from Comprehensive Datasets and Registries. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-11-01 Chloe Hutt Vater,Joseph Biederman,Maura DiSalvo,Hannah O'Connor,Haley Parker,K Yvonne Woodworth,Janet Wozniak,Stephen V Faraone
Objective: Attention-deficit/hyperactivity disorder (ADHD) treatment with stimulant products has been shown to be safe and effective; however, there are remaining concerns about their possible adverse effects on growth trajectories. We conducted a systematic review of the extant literature derived from ecologically valid databases and registries to assess the body of knowledge about the effects of
-
Caregiver Burden, Stress, and Relationship Cohesion Among Self-Identified Caregivers of Children with Pediatric Acute-Onset Neuropsychiatric Syndrome. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-11-01 Janice T Tona,Julie Ash,Emily Brown,Courtney Campagna,Kellie Kostek,Erin Lawton,Andrea Rieth,Machiko Tomita
Objective: Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) experience sudden onset neuropsychiatric symptoms after infection or other triggers. Symptoms range from mild to severe, potentially lasting days, weeks, months, or longer. Exacerbation-related functional decline presents in many aspects of daily life, generally accompanied by family stress and caregiver burden. We sought
-
Understanding and Managing New Onset Homicidal Ideation in an Adolescent with Depression. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-11-01 Keneil Brown,Yasin Bez,Kathy Truong,Manya Saaraswat,Barbara J Coffey
-
Factors Associated with Symptom Persistence in PANS: Part II-Presenting Features, Medical Comorbidities, and IVIG Treatment History. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-10-30 Denise Calaprice-Whitty,Angela Tang,Janice Tona
Objective: Individuals with Pediatric Acute Onset Neuropsychiatric Syndrome (PANS) experience neuropsychiatric symptoms following an infection or other trigger. Although PANS is typically described as relapsing-remitting, a large community-based 2017 study revealed a range of courses. The present study examined clinical predictors of symptom persistence, measured as % days symptom-free, in this same
-
Factors Associated with Symptom Persistence in PANS: Part I-Access to Care. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-10-30 Denise Calaprice-Whitty,Angela Tang,Janice Tona
Objective: Pediatric acute-onset neuropsychiatric syndrome (PANS) presents with abrupt neuropsychiatric symptoms, often after an immunologic trigger. A 2017 survey of 698 subjects found diagnostic delays to be associated with recurrences, suggesting that timely care impacts course. This secondary analysis explores the impact of barriers to care on symptom persistence. Methods: A 146-question online
-
Characteristic Similarities of Irritability Between Autism and Disruptive Mood Dysregulation Disorder. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-10-26 Pei-Yin Pan,Chin-Bin Yeh
Objective: Irritability in children with autism spectrum disorder (ASD) is prominent and often leads to distress to both autistic children and their families. However, the nature of irritability in autism and the difference from nonautistic children have rarely been examined. This study aimed to investigate the clinical characteristics of irritability in autism, and to compare the symptom profiles
-
Co-Occurring Anxiety in Youth with Tic Disorders: A Review. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-10-23 Yelizaveta Sapozhnikov,Jennifer Vermilion
Objective: To review the current state of the literature regarding anxiety symptoms and anxiety disorders in chronic tic disorder (CTD). Results: We conducted a literature search on anxiety and tic disorders. Anxiety symptoms and anxiety disorders are common in youth with CTD, with ∼30%-50% of youth with CTD having at least one co-occurring anxiety disorder. Tics often improve by young adulthood but
-
Improved Treatment Outcome with Haloperidol Decanoate and Amantadine in an Adolescent with Schizoaffective Disorder. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-10-01 Michelle Zaydlin,Julia A Bernal,Yasin Bez,Barbara J Coffey
-
Predictors and Moderators of Treatment Outcomes for Anxious Children Randomized to Computer-Assisted Cognitive Behavioral Therapy or Standard Community Care. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-10-01 Orri Smárason,Andrew G Guzick,Wayne K Goodman,Alison Salloum,Eric A Storch
Introduction: Computer-assisted cognitive behavioral therapy (CCBT) for childhood anxiety disorders may aid the dissemination of CBT, while maintaining treatment fidelity. Although CCBT is an effective intervention, not everyone benefits equally from treatment. Identifying patient characteristics that predict who will benefit from treatment and to what extent can help with matching patients to suitable
-
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-10-01 Christian Thurstone,Ryan Loh,Kristina Foreman,Christian A Thurstone,Chelsea Wolf
Introduction: Co-occurring cannabis use and psychosis is an increasing problem. No single behavioral or pharmacologic treatment has emerged as clearly superior. To address the gap, this nonrandomized, quality improvement project compares outcomes for adolescents with co-occurring cannabis use disorder and psychosis prescribed risperidone or aripiprazole. Materials and Methods: This project is a retrospective
-
Correction to: d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial, by Cutler et al. J Child Adolesc Psychopharmacol 2023;33(5):176-182; doi: 10.1089/cap.2023.0005. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-09-25
-
Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-09-07 Swarnava Sanyal,Ning Lyu,Chadi Calarge,Paul J Rowan,Rajender R Aparasu,Susan Abughosh,Hua Chen
Objectives: This study aimed to examine the association between abnormal readings of metabolic parameters detected during second-generation antipsychotic (SGA) treatment and the likelihood of receiving subsequent adverse drug event interventions. Methods: This was a nested case-control study conducted on patients 1-17 years of age with at least two prescriptions of SGAs between January 2010 and January
-
Evidence for Altered Electroencephalography Coherence in Depressed Adolescents with Suicidal Ideation and Behaviors. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-09-05 Can Ozger,Serhiy Chumachenko,Molly McVoy,Paul E Croarkin,Deniz Doruk Camsari
Introduction: Major depressive disorder (MDD) is a primary risk factor for suicide, which is one of the leading causes of death among adolescents worldwide. Understanding the heterogeneity of suicidality in adolescents with MDD is critical for suicide prevention and intervention discovery. Quantitative electroencephalography (EEG) is a promising tool to address the knowledge gaps related to the neurophysiological
-
A Novel Cognitive Training Program Targets Stimulus-Driven Attention to Alter Symptoms, Behavior, and Neural Circuitry in Pediatric Anxiety Disorders: Pilot Clinical Trial. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-09-05 Andrew T Drysdale,Michael J Myers,Jennifer C Harper,Meg Guard,Megan Manhart,Qiongru Yu,Michael T Perino,Joan L Luby,Deanna M Barch,Daniel S Pine,Chad M Sylvester
Objective: Pediatric anxiety disorders are associated with increased stimulus-driven attention (SDA), the involuntary capture of attention by salient stimuli. Increased SDA is linked to increased activity in the right ventrolateral prefrontal cortex (rVLPFC), especially in the portion corresponding to the ventral attention network (VAN). In this study, we present a small clinical trial using a novel
-
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-09-01 Aarti U Jerath,Sean E Oldak,Manasi S Parrish,Michelle Zaydlin,Stephon Martin,Keneil Brown,Valentina Cara,Barbara J Coffey
-
Re: "A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder" by Strawn et al.-Concerning Harm-Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-09-01 Martin Plöderl,Mark A Horowitz,Michael P Hengartner
-
Comparison of Possible Changes in Oxidative Stress, DNA Damage, and Inflammatory Markers in Children/Adolescents Diagnosed with Sluggish Cognitive Tempo and Children/Adolescents Diagnosed with Attention-Deficit/Hyperactivity Disorder. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-08-17 Ali Güven Kılıçoğlu,Telli Zadehgan Afshord,Songul Derin,Erdem Ertas,Pınar Coskun,Selman Aktas,Eray Metin Guler
Background: There has been a debate on whether sluggish cognitive tempo (SCT) differs from attention-deficit/hyperactivity disorder (ADHD). Although there have been many studies on metabolic parameters in relation to ADHD, no similar studies have been conducted on patients with SCT. We investigated whether there are differences between SCT and ADHD in terms of these factors. Subjects and Methods: Sixty-two
-
-
Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-08-09 Ifeoma Ezenwabachili,Emira Deumic Shultz,James A Mills,Vicki Ellingrod,Chadi A Calarge
Objective: To examine whether serotonin (5-HT) related genetic variants moderate the effects of selective serotonin reuptake inhibitors (SSRIs) on skeletal outcomes. Methods: Trabecular bone mineral density (BMD) at the radius, lumbar spine (LS) BMD, total body less head (TBLH) bone mineral content (BMC) and markers of bone metabolism (osteocalcin, C-terminal telopeptide of type I collagen [CTX-1]
-
Cognitive, Family, and Quality-of-Life Characteristics of Youth with Depression Associated with Bipolar Disorder. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-08-01 Arman Danielyan,Luis R Patino,Tessa Benanzer,Thomas J Blom,Jeffrey A Welge,Kiki D Chang,Caleb M Adler,Melissa P DelBello
Background: Depression associated with bipolar disorder (BD) is more common compared to mania. Cognitive, family, and quality-of-life (QOL) factors associated with pediatric bipolar depression are understudied. The goal of this study was to evaluate cognitive, family environmental, and QOL characteristics of youth with bipolar depression. Methods: Thirty-two youth (12-18 years of age) with BD type
-
Cannibalistic Ideation in a 14-Year-Old Girl: Psychosis or Trauma? J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-08-01 Sean E Oldak,Manasi S Parrish,Alyssa Cruz,Yasin Bez,Aarti Jerath,Barbara J Coffey
-
Understanding the Perspective of Youths on Undergoing Metabolic Monitoring While on Second-Generation Antipsychotics: Challenges, Insight, and Implications. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-07-27 Nisreen Aouira,Sohil Khan,Helen Heussler,Alison Haywood,Abdullah Karaksha,William Bor
Introduction: Prescription of second-generation antipsychotics (SGAs) in youths is rapidly increasing globally, despite the potential for significant adverse effects and long-term health consequences. A known adverse reaction resulting from SGAs is metabolic syndrome (MS). Youths exposed to antipsychotics are at higher risk than adults for adverse drug reactions, including adverse events such as MS
-
A Mobile Application Adjunct to Augment Cognitive-Behavioral Group Therapy for Adolescents with Social Anxiety: Feasibility and Acceptability Results from the Wiring Adolescents with Social Anxiety via Behavioral Interventions Pilot Trial. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-07-20 Bruno Biagianti,Christine Conelea,Sawsan Dabit,Daniel Ross,Katie L Beard,Elizabeth Harris,Erin Shen,Josh Jordan,Gail A Bernstein
Objective: Cognitive-Behavioral Group Therapy (CBGT) is an established treatment for Social Anxiety (SA). However, diagnostic recovery rate is only 20.5% in CBGT, and up to 50% of patients remain symptomatic posttreatment. Using videocalls to deliver digital CBGT (dCBGT) is feasible, cost-effective, and efficacious. Yet, the impact of dCBGT on social functioning remains limited, as dCBGT does not offer
-
Vascular Endothelial Growth Factor Polymorphism rs699947 Is Associated with Neurostructural Phenotypes in Youth with Bipolar Disorder. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-07-17 Nicole E Yan,Mikaela K Dimick,Kody G Kennedy,Clement C Zai,James L Kennedy,Bradley J MacIntosh,Benjamin I Goldstein
Background: Vascular endothelial growth factor (VEGF) may be relevant to bipolar disorder (BD) and brain structure. We evaluated VEGF rs699947 single-nucleotide polymorphism in relation to structural neuroimaging phenotypes in youth BD. Methods: We collected 3 T anatomical magnetic resonance images from 154 youth (79 BD and 75 healthy control [HC]) genotyped for VEGF rs699947. The participants were
-
Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-07-12 Paul P Yeung,Kimball A Johnson,Robert Riesenberg,Amelia Orejudos,Todd Riccobene,Hari V Kalluri,Paul R Malik,Shane Varughese,Robert L Findling
Objective: Cariprazine is a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat adults with schizophrenia and manic/mixed or depressive episodes associated with bipolar I disorder. This study, which is the first to evaluate cariprazine in pediatric patients with autism spectrum disorder (ASD) (including children 5-9 years of age) using an oral solution formulation
-
What Is the Added Benefit of Combining Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Youth with Obsessive Compulsive Disorder? A Bayesian Hierarchical Modeling Meta-Analysis. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-06-22 Eric M Mendez,Katherine K Dahlsgaard,John M Hjelmgren,Jeffrey A Mills,Vikram Suresh,Jeffrey R Strawn
Background: Treatment of obsessive-compulsive disorder (OCD) in children and adolescents frequently involves cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitors (SSRIs), or their combination. However, how adding CBT to SSRIs affects the trajectory and magnitude of improvement has not been evaluated meta-analytically. Methods: We performed a meta-analysis using weekly data from
-
Adherence to Clinical Guidelines for Dose Finding and Monitoring Methylphenidate Use: A Medical Record Audit in Child and Adolescent Mental Health Care and Pediatric Settings. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-06-01 Paul T Rosenau,Andrea Dietrich,Anne-Flore M Matthijssen,Renee Kleine-Deters,Gigi H H van de Loo-Neus,Jan K Buitelaar,Barbara J van den Hoofdakker,Pieter J Hoekstra
Background: Guideline adherence is important to ensure optimal and safe use of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). We investigated adherence to Dutch guidelines regarding dosing and monitoring of methylphenidate in child and adolescent mental health care and pediatric treatment settings. Methods: Five hundred six medical records of children
-
A Targeted Combined Pharmacotherapy Approach for Aggressive Behavior in a Child with Autism Spectrum Disorder. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-06-01 Michelle Zaydlin,Alyssa Cruz,Yasin Bez,Barbara J Coffey
-
Correction to: A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder, by Strawn et al. J Child Adolesc Psychopharmacol 2023;33(3):91-100; doi: 10.1089/cap.2023.0004. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-06-01
-
d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-06-01 Andrew J Cutler,Katsumi Suzuki,Brittney Starling,Kanan Balakrishnan,Marina Komaroff,Suzanne Meeves,Mariacristina Castelli,Ann Childress
Objectives: Amphetamines are a preferred treatment for attention-deficit/hyperactivity disorder (ADHD), with the dextroamphetamine transdermal system (d-ATS) providing an alternative to oral formulations. A pivotal trial of d-ATS in children and adolescents with ADHD met primary and key secondary endpoints. This analysis reports additional endpoints and safety findings from the pivotal trial and evaluates
-
An Investigation of Diversity in Childhood and Adolescent Antidepressant Studies: A Systematic Review. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-05-30 Elaine Ruiz,Avery Beatty,Lisa Weyandt
Objectives: Childhood mental illness is an ongoing public health crisis which is accompanied by an increase in antidepressant (i.e., serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors) use in children. Recent evidence highlighting the cultural differences in the utilization, efficacy, and tolerability of antidepressants in children underscores the need for diverse samples
-
Comorbidities in School-Age Children and Adolescents with Autism in an Ethnically Diverse Population: Brief Report. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-05-17 Maria Valicenti-McDermott,Danya Schlussel,Christine Hurley,Erin Rivelis,Carla Bernstein,Marie-Joane Cardin
Objectives: (1) To examine psychiatric and developmental comorbidities in school-age children and adolescents with Autism in a university-affiliated urban developmental center that serves children with developmental disabilities, and (2) to compare comorbidities by age groups. Methods: Review of all school-age children and adolescents evaluated and diagnosed with autism from 1/2019 to 1/2022. Data
-
A Double-Blind Placebo-Controlled Pilot Study of Topiramate in Manic Adolescents Treated with Olanzapine. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-05-02 Melissa P DelBello,Kaitlyn M Bruns,Thomas Bloom,Luis Rodrigo Patino Duran,Jeffrey Strawn,Caleb M Adler,Jeffrey Welge
Objective: To conduct a pilot study to examine topiramate for the treatment of weight gain associated with olanzapine in manic adolescents with bipolar disorder. Methods: We conducted a 12-week double-blind randomized placebo-controlled pilot study of topiramate (300-400 mg/day) versus placebo in manic youth (ages 10-18 years) with bipolar disorder who were treated with olanzapine (10-20 mg/day). The
-
Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-05-01 Rachael J Keefe,Angela D L Cummings,Ashley E Smith,Christopher S Greeley,Bethanie S Van Horne
Objective: To compare the prevalence of psychotropic medication prescriptions among youth in foster care with those among nonfoster youth on Medicaid. Methods: Children ages 1-18 years in a region of a large southern state who were enrolled in their respective Medicaid plan for at least 30 days between 2014 and 2016 and had at least one health care claim were included. Medicaid prescription claims
-
Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-05-01 Ann C Childress,Andrew J Cutler,Maitrey Patel,Charles Oh
Objective: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A 12-month, open-label safety study with SDX/d-MPH in children with ADHD showed that SDX/d-MPH was well tolerated and comparable with other methylphenidate products. In this post hoc analysis of the 12-month study, the objective
-
Rational Psychopharmacological and Psychotherapeutic Treatment of a 14-Year-Old Female with Functional Neurological Symptoms Disorder and Depression. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-05-01 Sean E Oldak,Julia A Bernal,Yasin Bez,Barbara J Coffey
-
Another Option for Aggression and Self-Injury, Alternative Benzodiazepines for Catatonia in Profound Autism. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-04-06 Joshua Ryan Smith,Tasia York,Samuel Warn,Darara Borodge,Donald L Pierce,D Catherine Fuchs
Introduction: Individuals with profound autism often present for inpatient care due to aggression. Diagnostic and treatment options are limited. Agitated catatonia is a treatable comorbidity in autism, which should be considered in cases of aggression. Preliminary data report high clinical response rates of catatonia in autism when treated with electroconvulsive therapy (ECT), with poor response to
-
Letter to the Editor: Delayed Fibrosis and Late Course Magnetic Resonance Imaging Findings in Clozapine-Induced Myocarditis in an Adolescent. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-04-06 Connor J Byeman,Rabia S Khan,Carissa Gunderson
-
A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-04-01 Jeffrey R Strawn,Leslie Moldauer,Rebekah D Hahn,Alexandria Wise,Kristina Bertzos,Beth Eisenberg,Edward Greenberg,Chengcheng Liu,Mallika Gopalkrishnan,Molly McVoy,James A Knutson
Objective: Generalized anxiety disorder (GAD) in children and adolescents is associated with substantial morbidity and increases the risk of future psychopathology. However, relatively few psychopharmacologic studies have examined treatments for GAD in pediatric populations, especially in prepubertal youth. Methods: Children and adolescents aged 7-17 years of age with a primary diagnosis of GAD were
-
Glucocorticoid-Induced Psychosis in Children and Adolescents: A Systematic Review. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-04-01 Parisa Fani-Molky,Jarrod Bradley,Mark S Cooper
Objectives: Knowledge is limited regarding the adverse effects of therapeutic glucocorticoids on pediatric mental health outcomes. Glucocorticoid-induced psychosis (GIP) is a rare but severe side effect of high-dose glucocorticoid therapy in children and adolescents. This study identified reported pediatric cases of GIP, based on DSM-5 criteria, and defined its presentation, treatments, and outcomes
-
Multivariable Prediction Modeling of Antidepressant Initiation in Unipolar Depressed Adolescents: A Secondary Analysis of the IMPACT Trial. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-04-01 Darren Courtney,Madison Aitken,Wei Wang,Sheng Chen,Paul Wilkinson,Peter Szatmari,Ian Goodyer
Introduction: This secondary analysis of data collected in a randomized controlled trial (RCT) for the treatment of depression in adolescents aimed to test prediction models relating antidepressant (AD) initiation to clinical variables. Methods: The primary study was an RCT where adolescents (ages 11-17) with depression were assigned one of three outpatient psychotherapies over 86 weeks. The current
-
Navigating Pharmacological Treatment in an Adolescent with New Onset Psychosis: Clinical, Pharmacological, and Cultural Challenges. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-04-01 Michelle Zaydlin,Melanie Gershman,Alexandra Coppa,Jessica D Leuchter,Yasin Bez,Barbara J Coffey
-
Correction to: The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives, by Klein et al. J Child Adolesc Psychopharmacol 2020;30(6):376-380; doi: 10.1089/cap.2019.0184. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-03-23
-
Comparison of Fidgeting in Adolescents with Attention-Deficit/Hyperactivity Disorder Between Before and After Stimulant Medication Intake. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-03-10 Shelby Sydenstricker,Alexandra Moore,Kyoko Nagao
Objective: Fidgeting is a common symptom in patients with attention-deficit hyperactivity disorder (ADHD). The current study investigated ADHD stimulant medication effects on fidgeting in adolescents with ADHD during a short research study session using wrist-worn accelerometers. Method: Adolescents with ADHD who had been taking stimulant medications (ADHD group) and adolescents without ADHD (control
-
Pharmacotherapy May Attenuate the Risk of Child Abuse in Attention-Deficit/Hyperactivity Disorder from the Real-World Evidence. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-03-01 Cian-Cian Lin,Chi-Hsiang Chung,Wu-Chien Chien,Nian-Sheng Tzeng
Objective: Psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), may serve as a risk factor for child abuse. Methods: This study aimed to evaluate the association between children and adolescents with ADHD diagnosis and the risk of child abuse. The effectiveness of a pharmacological intervention on reducing the risk of child abuse was also assessed. A nationwide, population-based
-
Prevalence and Factors Affecting the Use of Antipsychotics and Antipsychotic Polypharmacy in a Child and Adolescent Psychiatry Inpatient Service. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-03-01 Ahmet Büber,Erdal Görkem Gavcar,Ömer Başay,Gülşen Ünlü,Bürge Kabukçu Başay,Hande Şenol
Objective: We aimed to examine the antipsychotics used by patients hospitalized in the child and youth inpatient service providing tertiary care to investigate whether there is a difference between admission and discharge, polypharmacy, which antipsychotics are used, and which psychotropics are used concomitant with antipsychotics. Methods: Research data were collected retrospectively from all children
-
Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-03-01 Sijie Yu,Sihao Shen,Ming Tao
Background: Non-stimulant guanfacine is a common second-line medication for attention-deficit hyperactivity disorder (ADHD). Numerous randomized controlled trials (RCTs) have explored the efficacy of guanfacine in ADHD treatment. This meta-analysis combined data from selected RCTs to analyze the efficacy and safety of guanfacine in treating ADHD. Methods: RCTs were identified from published sources
-
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-02-20 Ann C Childress,Andrea Marraffino,Andrew J Cutler,Charles Oh,Matthew N Brams
Objective: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A pivotal double-blind (DB) study of children aged 6-12 years with ADHD demonstrated efficacy for ADHD with good tolerability. In this study, we assessed the safety and tolerability of daily oral SDX/d-MPH for up to 1 year in children
-
Relationship Between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-02-02 Botao Ma, Wenxuan Zhao, Hongzhen Fan, Yajun Yun, Siyuan Qi, Huimei An, Fude Yang
Objective: To investigate the relationship between plasma aripiprazole (ARI) and its metabolite dehydroaripiprazole (DARI) concentrations and prolactin (PRL) levels in Chinese children and adolescents.
-
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-02-02 Stephen V. Faraone, Ann C. Childress, Roberto Gomeni, Eman Rafla, Judith C. Kando, Lori Dansie, Payal Naik, Antonio Pardo
Objective: To evaluate the treatment effect size throughout the day of amphetamine extended-release oral suspension (AMPH EROS; Tris Pharma, Inc., Monmouth Junction, NJ, USA) in a laboratory classroom study conducted in children aged 6–12 years with attention-deficit/hyperactivity disorder (ADHD).
-
Clonazepam Treatment of Adolescent Catatonia in A Setting of Lorazepam-Related Hypotension. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-02-01 Dennis Valerstain,Michelle Zaydlin,Yasin Bez,Barbara J Coffey
-
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-02-01 Alice Lineham,Victor J Avila-Quintero,Michael H Bloch,Jennifer Dwyer
Objective: Ketamine has proven effective as a rapid-acting antidepressant agent. Several adult studies have investigated the association between ketamine's acute dissociative effects and depression response, but no studies have examined the association in adolescents with treatment-resistant depression (TRD). Methods: We conducted a secondary data analysis of 16 adolescent participants who participated
-
Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES). J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2023-02-01 Francesca Kolitsopoulos,Sara Ramaker,Scott N Compton,Samuel Broderick,John Orazem,Weihang Bao,Yuliya Lokhnygina,Kristina Marschall,Phillip Chappell
Objective: To describe the results of the Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES) outcome measures of cognitive, emotional, and physical development following long-term treatment with sertraline (for up to 3 years) in children and adolescents aged 6-16 years. Methods: SPRITES was a long-term, multicenter, open-label, prospective observational study designed to compare physical
-
Psychopharmacological Treatment Algorithms of Manic/Mixed and Depressed Episodes in Pediatric Bipolar Disorder J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2022-12-21 Elizabeth Hobbs, Rachel Reed, Boris Lorberg, Adelaide S. Robb, Julia Dorfman
Introduction: Pediatric bipolar disorder (PBD) is a severe psychiatric illness diagnosed before the age of 18, which is associated with extreme shifts in mood characterized by manic and depressive episodes. In 2005, AACAP published algorithms to guide pharmacological treatment of manic/mixed episodes associated with PBD. At that time, lithium was the only Food and Drug Administration (FDA)-approved
-
Preliminary Observations of Resting-State Magnetoencephalography in Nonmedicated Children with Obsessive-Compulsive Disorder J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2022-12-21 Vinh Tan, Colleen Dockstader, Iska Moxon-Emre, Sandra Mendlowitz, Reva Schacter, Marlena Colasanto, Aristotle N. Voineskos, Aquila Akingbade, Eman Nishat, Donald J. Mabbott, Paul D. Arnold, Stephanie H. Ameis
Background: Cortico-striato-thalamo-cortical (CSTC) network alterations are hypothesized to contribute to symptoms of obsessive-compulsive disorder (OCD). To date, very few studies have examined whether CSTC network alterations are present in children with OCD, who are medication naive. Medication-naive pediatric imaging samples may be optimal to study neural correlates of illness and identify brain-based
-
Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2022-12-21 Gilad Fainberg, Yael Leitner, Dinah Zur, Ainat Klein, Daphna Mezad-Koursh
Objective: To evaluate the short-term effect of dexmethylphenidate (D-MPH) on visual acuity (VA), pupil size, anterior chamber depth, and accommodation-convergence reflex in children treated with D-MPH for attention-deficit/hyperactivity disorder (ADHD).
-
Reported Side or Adverse Effects Associated with Medication Nonadherence Among Adolescents and Young Adults with Attention-Deficit/Hyperactivity Disorder J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2022-12-21 Lucy Barnard-Brak, Carolina Kudesey
Background and Objective: The purpose of this study was to determine what side effects were most associated with medication nonadherence as reported by adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD).
-
Clozapine and Constipation: Considerations in an Obese Adolescent Girl. J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2022-12-01 Diane Rhee,Morgan Jones,Kate M Mitchell,Jacqueline Segal,Timothy Rice,Barbara J Coffey
-
A Predictive Biomarker Model Using Quantitative Electroencephalography in Adolescent Major Depressive Disorder J. Child Adolesc. Psychopharmacol. (IF 1.9) Pub Date : 2022-11-15 Molly McVoy, Serhiy Chumachenko, Farren Briggs, Farhad Kaffashi, Kenneth Loparo
Background: With evolving understanding of psychiatric diagnosis and treatment, demand for biomarkers for psychiatric disorders in children and adolescents has grown dramatically. This study utilized quantitative electroencephalography (qEEG) to develop a predictive model for adolescent major depressive disorder (MDD). We hypothesized that youth with MDD compared to healthy controls (HCs) could be